Last updated: May 24, 2026
Gentamicin sulfate is a widely supplied, commoditized aminoglycoside active pharmaceutical ingredient (API) and finished-dose drug. The supplier landscape splits into (1) API manufacturers that produce gentamicin sulfate for global customers and (2) finished-dose manufacturers/packagers that supply markets under their own dossiers and regulatory approvals. Supply planning is driven by grade (API vs injectable vs ophthalmic/otologic), salt form (gentamicin sulfate), product presentation, and quality system fit (DMF/CEP, sterile manufacturing capacity, and controlled substance handling is not typically a factor).
What companies supply gentamicin sulfate API for pharmaceutical manufacturers?
Featured answer: API supply comes from multiple global producers, including fermentation-based specialty antibiotics manufacturers and bulk API players that support sterile and non-sterile formulations.
Common gentamicin sulfate API sourcing paths
Most buyers source gentamicin sulfate via one of these routes:
- Direct API purchase from DMF-holding API manufacturers for incorporation into their own finished products.
- Contract manufacturing of sterile drug products where gentamicin sulfate is provided (or co-supplied under a supply agreement) to the CMO.
- Finished-dose sourcing where the buyer imports a ready-to-market product and uses it as supply coverage while managing regulatory submissions.
Supply-chain concentration and why it matters
Gentamicin is mature and broadly manufactured, but sterile injectable capacity and aseptic packaging tend to be the constraint during demand spikes. Buyers typically diversify across at least two qualified API sources to reduce lead-time and lot-sourcing risk.
Which gentamicin sulfate manufacturers supply the US market (injectable and ophthalmic/otologic)?
Featured answer: The US market is supplied by branded legacy holders and authorized generics, with multiple NDA/ANDA holders listing on the FDA Orange Book for gentamicin sulfate products.
How to map supplier coverage
To identify US-facing suppliers, you match:
- Drug product (injection, ophthalmic solution/ointment, otic solution/ear drops)
- Strength (commonly 10 mg/mL for injectable in many markets; ophthalmic and otic strengths vary by product)
- Dosage form (sterile solution vs non-sterile topical)
- Orange Book listing holder (applicant) and manufacturer of record (where listed)
This matters operationally because “supplier” can mean either the API manufacturer or the finished-dose manufacturer on the label.
What is the Orange Book status of gentamicin sulfate products and who are the ANDA holders?
Featured answer: Many gentamicin sulfate products have long-standing ANDA coverage, and multiple applicants may be listed by strength and dosage form.
Orange Book fields that drive sourcing
For each gentamicin sulfate product, the Orange Book listing supports sourcing decisions through:
- Active ingredient and strength
- Dosage form
- Applicant/Holder
- Patent and exclusivity blocks (often expired for older products)
- Therapeutic equivalence codes for substitution planning
Which suppliers cover sterile gentamicin sulfate injections vs ophthalmic/otic drops?
Featured answer: Sterile injectables are typically sourced from suppliers with aseptic capability and validated sterilization/aseptic processing, while ophthalmic/otic products add tight sterility and preservative/viscosity specifications.
Sterile injection supply: critical constraints
Key bottlenecks in sourcing gentamicin sulfate injection include:
- Aseptic fill-finish capacity
- Media fills and sterility assurance level controls
- Lot release timelines and stability program readiness
Ophthalmic/otic supply: formulation and sterility
For drops and solutions, suppliers must meet:
- Particle and bioburden specifications
- Preservative compatibility (for multi-dose containers)
- Container-closure integrity and leak testing
What formulations are supplied for gentamicin sulfate and which suppliers typically produce each?
Featured answer: Common gentamicin sulfate formats include injections and topical ophthalmic/otologic formulations; supplier specialization often tracks dosage form.
Key product buckets
- Injection: sterile solution presentations for systemic use
- Ophthalmic: gentamicin sulfate eye drops or ophthalmic ointments
- Otic: gentamicin sulfate ear drops/solutions (often combined with other actives in some markets, depending on approved labeling)
How do pricing and contract terms differ across gentamicin sulfate API vs finished doses?
Featured answer: API is traded under longer-term supply agreements tied to fermentation yield and batch release costs; finished doses add packaging, sterile manufacturing, and regulatory unit costs, which dominate in shortages.
What drives cost
- API yield and fermentation batch success
- Sterile CMO or manufacturer utilization rates
- Packaging SKUs and container availability
- Regulatory backlog for variation approvals and labeling updates
What generic entry risks exist for gentamicin sulfate products?
Featured answer: For mature gentamicin products, the primary risk is not patent exclusivity but manufacturing and regulatory continuity, including sterile supply capacity and quality deviations that can trigger recalls or supply interruptions.
Paragraph IV and patent challenges: why they are usually not the main driver
For older antibiotics, patent estates are often expired. Entry risk typically comes from:
- Inability to meet process validation or sterility requirements
- Delays in regulatory release testing
- Distribution channel acceptance timing
Which suppliers are likely best positioned to scale gentamicin sulfate during shortages?
Featured answer: Scale typically favors suppliers with:
- Confirmed sterile fill-finish capacity
- Multi-source API qualification
- Redundant aseptic suites and rapid release logistics
Operational diligence points
- Supplier’s historical shipment cadence
- Batch failure and deviation frequency
- On-time lot release performance
- Shelf-life and stability margin for commercial supply
What manufacturing/IP barriers affect gentamicin sulfate supply?
Featured answer: Gentamicin sulfate has limited active IP friction for API synthesis at this point, but practical barriers are quality systems and aseptic process know-how rather than enforceable composition-of-matter patents.
Where barriers show up
- Sterile processing validation and facility qualification
- Analytical method transfer and cross-validation
- Container closure qualification and extractables/leachables
How does gentamicin sulfate API sourcing compare with gentamicin base or other salts?
Featured answer: Sourcing is generally organized by salt form. Gentamicin sulfate is a defined target with established compendial methods and typical conversion assumptions in formulation.
Buyer considerations
- Salt form affects potency calculations for labeling and formulation equivalency
- Specifications (assays, impurities, residual solvents) must match regulatory expectations
- Analytical method alignment across supplier changes
Key Takeaways
- Gentamicin sulfate supply is broad, with multiple API and finished-dose suppliers globally, but sterile injectable capacity is the usual scaling constraint.
- “Supplier” in procurement can mean API source or finished-dose manufacturer; match the definition to the use case.
- Orange Book listings help identify US applicants and substitute-ready generics by dosage form and strength.
- Supply continuity risk is dominated by manufacturing execution, sterility assurance, and lot release performance more than by new patent barriers.
FAQs
- How do I distinguish gentamicin sulfate API suppliers from finished-dose manufacturers in procurement?
- What specifications should buyers require for gentamicin sulfate API (assay, impurities, microbial limits)?
- Which dosage forms of gentamicin sulfate are most sensitive to aseptic manufacturing constraints?
- How should companies manage multi-source qualification when switching gentamicin sulfate API suppliers?
- What Orange Book fields are most useful for finding substitute-ready gentamicin sulfate generics by strength?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- European Medicines Agency. Public assessment reports and related product information for gentamicin-containing products. https://www.ema.europa.eu/
